Diabetes Care:DPTRS有助鉴别1型糖尿病临床前状态

2012-05-06 沐雨译 医学论坛网

  有研究者评价了糖尿病预防试验—1型危险评分(DPTRS)对于2年内有可能进展为1型糖尿病的个体的鉴别能力。结果发现,DPTRS阈值为9.00可鉴别在2年内极可能被常规诊断为1型糖尿病的患者,这对于糖尿病临床前期非常重要。该研究4月30日在线发表于《糖尿病护理》(Diabetes Care)杂志。   DPTRS的组分包括C肽和口服葡萄糖耐力试验的葡萄糖指数,以及年龄和体质指数,该评

  有研究者评价了糖尿病预防试验—1型危险评分(DPTRS)对于2年内有可能进展为1型糖尿病的个体的鉴别能力。结果发现,DPTRS阈值为9.00可鉴别在2年内极可能被常规诊断为1型糖尿病的患者,这对于糖尿病临床前期非常重要。该研究4月30日在线发表于《糖尿病护理》(Diabetes Care)杂志。

  DPTRS的组分包括C肽和口服葡萄糖耐力试验的葡萄糖指数,以及年龄和体质指数,该评分来自糖尿病预防试验—1型(DPT-1),并在TrialNet自然史研究(TNNHS)得到验证。

  评价结果表明,在DPT-1和TNNHS中,DPTRS阈值超过9.00后的2年危险分别为0.88和0.77。在DPT-1中,首次发生血糖代谢障碍和2小时血糖首次达到为190~199 mg/dl后的2年进展危险更低。在DPT-1中发生1型糖尿病的患者中,超过9.00阈值先于常规诊断0.81 (± 0.53)年。当首次超出9.00的阈值时,负荷后C肽水平较诊断时的水平显著升高。

  链接:

  The Application of the Diabetes Prevention Trial–Type 1 Risk Score for Identifying a Preclinical State of Type 1 Diabetes

  



    

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1636497, encodeId=bb73163649e9f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Jul 03 21:06:00 CST 2012, time=2012-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900946, encodeId=438f190094698, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Nov 21 12:06:00 CST 2012, time=2012-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997059, encodeId=a2a3199e05990, content=<a href='/topic/show?id=cfd762251f' target=_blank style='color:#2F92EE;'>#DPT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6225, encryptionId=cfd762251f, topicName=DPT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Wed Oct 31 10:06:00 CST 2012, time=2012-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759135, encodeId=961d1e59135fc, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jun 13 21:06:00 CST 2012, time=2012-06-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1636497, encodeId=bb73163649e9f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Jul 03 21:06:00 CST 2012, time=2012-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900946, encodeId=438f190094698, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Nov 21 12:06:00 CST 2012, time=2012-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997059, encodeId=a2a3199e05990, content=<a href='/topic/show?id=cfd762251f' target=_blank style='color:#2F92EE;'>#DPT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6225, encryptionId=cfd762251f, topicName=DPT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Wed Oct 31 10:06:00 CST 2012, time=2012-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759135, encodeId=961d1e59135fc, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jun 13 21:06:00 CST 2012, time=2012-06-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1636497, encodeId=bb73163649e9f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Jul 03 21:06:00 CST 2012, time=2012-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900946, encodeId=438f190094698, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Nov 21 12:06:00 CST 2012, time=2012-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997059, encodeId=a2a3199e05990, content=<a href='/topic/show?id=cfd762251f' target=_blank style='color:#2F92EE;'>#DPT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6225, encryptionId=cfd762251f, topicName=DPT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Wed Oct 31 10:06:00 CST 2012, time=2012-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759135, encodeId=961d1e59135fc, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jun 13 21:06:00 CST 2012, time=2012-06-13, status=1, ipAttribution=)]
    2012-10-31 kord1982
  4. [GetPortalCommentsPageByObjectIdResponse(id=1636497, encodeId=bb73163649e9f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Jul 03 21:06:00 CST 2012, time=2012-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900946, encodeId=438f190094698, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Nov 21 12:06:00 CST 2012, time=2012-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997059, encodeId=a2a3199e05990, content=<a href='/topic/show?id=cfd762251f' target=_blank style='color:#2F92EE;'>#DPT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6225, encryptionId=cfd762251f, topicName=DPT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Wed Oct 31 10:06:00 CST 2012, time=2012-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759135, encodeId=961d1e59135fc, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jun 13 21:06:00 CST 2012, time=2012-06-13, status=1, ipAttribution=)]
    2012-06-13 zhaojie88

相关资讯

NEJM:GAD-alum抗原治疗未能阻止1型糖尿病进展

 根据2月2日的《新英格兰医学杂志》(New England Journal of Medicine)上发表的一篇报告,在一项对新发1型糖尿病患者进行的Ⅲ期临床试验中,使用谷氨酸脱羧酶65与钒结合的抗原治疗未能诱导免疫耐受和阻止刺激后血清C肽的降低。之前的Ⅱ期研究显示,在一个诊断后立即开始治疗的患者亚组中,谷氨酸脱羧酶65-kD同工酶(GAD65)与钒结合(GAD-alum)的治疗使刺激

Nat rev2011内分泌研究进展:1型糖尿病

文献标题:Type 1 diabetes mellitus in 2011: Heterogeneity of T1DM raises questions for therapy.(全文) 期刊来源:Nature reviews. Endocrinology.2012-02;8(2):69-70. 期刊影响因子:9.191 1型糖尿病2011:T1DM的异质性对其治疗提出质疑